Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. It operates in two segments, Biopharmaceuticals Products and Services and Specialty Pharmaceuticals. Biopharmaceuticals Products and Services segment develops late-stage biopharmaceutical products. Its products under development include SinuNase, a formulation to treat chronic rhinosinusitis, a long-term inflammatory condition of the paranasal sinuses; and Biovaxid, a patient-specific cancer vaccine focusing on the treatment of follicular nonHodgkin’s lymphoma. This segment also includes analytical and consulting business, which provides a range of services relating to biopharmaceutical product development. In addition, it produces custom biologic products and cell culture instruments and systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions. Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by third-party development partners. Its specialty pharmaceutical products include Xodol, a narcotic pain formulation; Respi~TANN, a prescription antitussive decongestant for temporary relief of cough and nasal congestion; line of six HISTEX products for the cough, cold, and allergy prescription market; and two products, which the company co-promote. This segment’s other products under development include MD Turbo, a breath-actuated inhaler device used by patients with asthma and chronic obstructive pulmonary disease; Emezine, a transbuccal drug designed to control nausea and vomiting; and eight additional narcotic pain formulations for the treatment of moderate to moderately severe pain. Accentia Biopharmaceuticals was founded in 2002 and is based in Tampa, Florida.